MEC Plus Full List View

By /

MEC Plus

Breast Cancer Update in Hormone Sensitive Breast Cancer
Breast Cancer Update in Hormone Sensitive Breast Cancer
Lauren Carcas, MD
 View Video
New Developments in Metastatic Breast Cancer: Immunotherapy and Novel Therapeutic Pathways
New Developments in Metastatic Breast Cancer: Immunotherapy and Novel Therapeutic Pathways
Joyce O’Shaughnessy, MD
 View Video
New Developments in EGFR and K-RAS Therapies in NSCLC
New Developments in EGFR and K-RAS Therapies in NSCLC
Edgardo S. Santos, MD, FACP
 View Video
Updates on Targeting ALK, ROS1 ,and RET in NSCLC
Updates on Targeting ALK, ROS1 ,and RET in NSCLC
Jessica Lin, MD
 View Video
Most Relevant Data on Immunotherapy in Neo-Adjuvant, Adjuvant, and Metastatic NSCLC
Most Relevant Data on Immunotherapy in Neo-Adjuvant, Adjuvant, and Metastatic NSCLC
Luis E. Raez, MD, FACP, FCCP
 View Video
The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET
The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET
Jason Porter, MD
 View Video
New Developments in CLL
New Developments in CLL
Javier Pinilla-Ibarz, MD, PhD
 View Video
Most Relevant News in Multiple Myeloma in 2023
Most Relevant News in Multiple Myeloma in 2023
Sergio Giralt, MD, FACP, FASTCT
 View Video
Modern Challenges and New Options for B-cell NHL
Modern Challenges and New Options for B-cell NHL
Eduardo Sotomayor, MD
 View Video
Update on T-Cell Lymphomas
Update on T-Cell Lymphomas
Juan Carlos Ramos, MD
 View Video
What’s After PACIFIC? Can We Raise the Bar?
What’s After PACIFIC? Can We Raise the Bar?
Jhanelle Gray, MD
 View Video
What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?
What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?
Ticiana Leal, MD
 View Video
Updates in Bispecific Antibodies in NSCLC
Updates in Bispecific Antibodies in NSCLC
Lyudmila Bazhenova, MD
 View Video
TROP-2 and AXL as Targets in NSCLC
TROP-2 and AXL as Targets in NSCLC
Stephen Liu, MD
 View Video
The Role of Co-Mutations with Immunotherapy Response in NSCLC
The Role of Co-Mutations with Immunotherapy Response in NSCLC
Ferdinando Skoulidis, MD
 View Video
The New Role of Microbiome in Lung Cancer Immunotherapy
The New Role of Microbiome in Lung Cancer Immunotherapy
David Carbone, MD
 View Video
The Importance of TIME in Cancer Fight: How to Target It?
The Importance of TIME in Cancer Fight: How to Target It?
Hossein Borghaei, DO
 View Video
Targeting CEACAM5 and ROR1/ROR2 in NSCLC
Targeting CEACAM5 and ROR1/ROR2 in NSCLC
Paul Bunn, MD
 View Video
Systemic Therapies for Mesothelioma
Systemic Therapies for Mesothelioma
Jorge E. Gomez, MD
 View Video
Strategies to Target Minimal Residual Disease
Strategies to Target Minimal Residual Disease
Christine M. Lovly, MD, PhD
 View Video
Stage III Non-Surgical NSCLC: Optimal Radiation Therapy Approach
Stage III Non-Surgical NSCLC: Optimal Radiation Therapy Approach
Puneeth Iyengar, MD
 View Video
Stage III Non-Surgical Candidate NSCLC – Controversies in this Arena (Tumors with Actionable Genes and No PD-L1 Expression)
Stage III Non-Surgical Candidate NSCLC – Controversies in this Arena (Tumors with Actionable Genes and No PD-L1 Expression)
Corey Langer, MD
 View Video
ROS-1 & B-Raf Inhibitors: New Developments
ROS-1 & B-Raf Inhibitors: New Developments
Julia Rotow, MD
 View Video
Role of SHP2 Inhibitors Alone or in Combination
Role of SHP2 Inhibitors Alone or in Combination
Rachel Sanborn, MD
 View Video
Role of Radiotherapy in TIME: Good? Bad? Don’t know?
Role of Radiotherapy in TIME: Good? Bad? Don’t know?
Puneeth Iyengar, MD
 View Video
Role of Interleukins in TIME to Improve Immunotherapy Efficacy
Role of Interleukins in TIME to Improve Immunotherapy Efficacy
Suresh Ramalingam, MD
 View Video
RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up?
RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up?
John Heymach, MD
 View Video
Radiation Induced Immune-Response in NSCLC
Radiation Induced Immune-Response in NSCLC
Jeffrey Bradley, MD
 View Video
Predictive Biomarkers for SCLC
Predictive Biomarkers for SCLC
Janakiraman Subramanian, MD
 View Video
PARP Inhibitors in SCLC
PARP Inhibitors in SCLC
Charles Rudin, MD, PhD
 View Video

Displaying 571 - 600 of 2,875